Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of February 2021, with a specific report date of February 10, 2021. The registrant is a foreign private issuer based in Jerusalem, Israel, operating in the pharmaceutical sector.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event disclosed is the full exercise of the underwriter's over-allotment option in a follow-on offering announced on February 10, 2021. No comparative financial data or prior period changes are detailed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the announcement of the over-allotment exercise. The document explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the total capital raised from the follow-on offering including the over-allotment portion.
- Confirm the final number of shares issued upon the full exercise of the option.
- Review the full press release (Exhibit 99.1) for details on the use of proceeds.
- Check subsequent filings for updated capitalization tables reflecting this transaction.